




Cite this: *Chem. Sci.*, 2019, 10, 701

All publication charges for this article have been paid for by the Royal Society of Chemistry

# Click to enter: activation of oligo-arginine cell-penetrating peptides by bioorthogonal tetrazine ligations†

Saskia A. Bode,‡ Suzanne B. P. E. Timmermans,  ‡ Selma Eising, Sander P. W. van Gemert, Kimberly M. Bonger \* and Dennis W. P. M. Löwik \*

Cell-penetrating peptides are able to transport a wide variety of cargo across cell membranes. Although promising, they are not often considered for therapeutic purposes as they lack controllable activity and cell selectivity. We have developed an activation strategy based on a split octa-arginine cell-penetrating peptide (CPP) that can be activated by means of bioorthogonal ligation. To this end we prepared two non-penetrating tetra-arginine halves, functionalized either with a tetrazine or with a complementary bicyclo[6.1.0]nonyne (BCN) group. We demonstrate that an active octa-arginine can be reconstituted *in situ* upon mixing the complementary split peptides. The resulting activated peptide is taken up as efficiently as the well-established cell-penetrating peptide octa-arginine. The activation of the oligo-arginines can also be achieved using *trans*-cyclooctene (TCO) as a ligation partner, while norbornene appears too kinetically slow for use *in situ*. We further show that this strategy can be applied successfully to transport a large protein into living cells. Our results validate a promising first step in achieving control over cell penetration and to use CPPs for therapeutic approaches.

Received 3rd October 2018  
Accepted 24th October 2018

DOI: 10.1039/c8sc04394a

rsc.li/chemical-science

## Introduction

Cell-penetrating peptides (CPPs) have the ability to penetrate the otherwise impermeable plasma membrane. They can transport large cargoes and as a result are potential candidates for delivery of bioactive molecules.<sup>1–5</sup> Although the use of CPP-cargo constructs for cellular delivery is promising, CPPs are hardly cell-type specific, and there is no temporal control over their uptake.<sup>6–8</sup> The use of CPPs for therapeutic purposes would greatly benefit if cell-type selectivity and control over their moment of uptake could be induced.<sup>9</sup> Various studies have been reported on the development of activatable CPPs, using several triggers, such as a change in pH,<sup>10</sup> irradiation,<sup>11–13</sup> or enzymatic reactions.<sup>14,15</sup> Most of these activation strategies promise to induce cellular uptake. They generally depend on the properties of the targeted tissue or cell type, making them sensitive for changes in the targeted environment. Now, we think it would be beneficial to develop an activation strategy that does not need an enzymatic activity or pH change. When we would combine it with a targeting strategy it can rely on any receptor or other type of marker and therefore would be more generally applicable.

Previously, we demonstrated an activation strategy for oligo-arginines.<sup>16,17</sup> For these peptides it is known that a minimum amount of six arginine residues is needed to induce cellular uptake.<sup>18,19</sup> Making use of this characteristic, a split-CPP approach was designed that involved truncated oligo-arginines consisting of three to five arginine residues and a C-terminal cysteine. These peptides were assembled and activated through disulfide bridge formation with complementary oligo-arginines containing an N-terminal cysteine residue. Whereas the truncated split peptides did not induce uptake in HeLa cells, the assembled octa- and nona-arginines were efficient CPPs. Although we demonstrated that activation of short oligo-arginine peptides is possible by extension of their sequence, its dependency on the formation of disulfide bridges hampers their use for *in situ* activation due to the dominant oxidative environment and the presence of potentially interfering thiols in many cellular environments. To overcome this limitation, and to circumvent possible non-specific interactions of the split CPPs with endogenous biomolecules, we investigated alternative activation strategies based on the bioorthogonal tetrazine ligation (Fig. 1).<sup>20</sup>

## Results and discussion

### Design and synthesis

The tetrazine ligation with alkenes or alkynes is based on an inverse electron demand Diels–Alder (IEDDA) reaction and has been used previously for several *in vivo* applications.<sup>21–26</sup> For our

Institute for Molecules and Materials, Radboud University, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands. E-mail: dennis.lowik@ru.nl; k.bonger@science.ru.nl

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc04394a

‡ These authors contributed equally.






Fig. 1 Overview of the click to enter strategy.

*in situ* activation strategy of CPPs we synthesized several truncated tetra-arginines equipped with a tetrazine moiety or with a complementary alkene and alkyne reactive group. We first prepared a tetra-arginine, of which the C-terminus was connected to a 3-aminobenzyl-6-methyl substituted tetrazine<sup>27</sup> (**R4-Tz**, Fig. 2). We selected this tetrazine, because of its stability and solubility in aqueous environments. Although the reactivity of this tetrazine is moderate compared to other more electron-deficient less stable tetrazines, the reaction rates are still suitable for biological applications.<sup>28</sup> Further, we labelled the N-terminus with fluorescein isothiocyanate (FITC), linked *via*




Fig. 2 Structures of oligo-arginine peptides used in this study.

a 6-aminohexanoic acid spacer, to enable the visualization of cellular uptake with confocal laser scanning microscopy (CLSM) and quantification using flow cytometry. As an activation partner for the **R4-Tz** we first explored a tetra-arginine containing the bioorthogonal bicyclo[6.1.0]nonyne (**BCN-R4**).<sup>25,29</sup> In addition, we synthesized fluorescently labelled octa-arginine **R8** as a reference CPP and pre-conjugated **R4-b-R4** – prepared from **R4-Tz** and **BCN-R4** – that allowed us to determine the activity of the fully reconstituted CPP and find suitable conditions for uptake (Fig. 2).

### Uptake of pre-ligated conjugates

The mechanism of uptake of arginine-rich CPPs is dependent on their concentration and their structures,<sup>30</sup> therefore we started by comparing the uptake of CPP **R8** with that of the pre-ligated peptide **R4-b-R4** at 5  $\mu\text{M}$ , 10  $\mu\text{M}$ , 15  $\mu\text{M}$  and 20  $\mu\text{M}$  using confocal fluorescence microscopy (Fig. 3). As a control, we measured the uptake of the truncated peptide **R4-Tz**. At low concentrations (5  $\mu\text{M}$  and 10  $\mu\text{M}$ ), we did not observe any uptake of the truncated peptide **R4-Tz**, which was in accordance with earlier findings that demonstrated that at least six arginines within one sequence are required for efficient cellular uptake.<sup>16</sup> At higher concentrations (15  $\mu\text{M}$  and 20  $\mu\text{M}$ ) we observed some




Fig. 3 CLSM micrographs corresponding to cellular uptake studies in HeLa cells. The concentration of the CPP increases from top to bottom (5, 10, 15 and 20  $\mu\text{M}$ ). The experiments were performed with reference peptide **R8**, pre-ligated **R4-b-R4** and truncated **R4-Tz** at 37  $^{\circ}\text{C}$ , with an incubation time of 30 minutes in serum-containing medium.



minor cellular internalization. The pre-ligated peptide **R4-b-R4** and **R8** were taken up at all concentrations, however, the mechanism of uptake varied considerably between the peptide concentrations (Fig. 3). At low concentrations, **R8** and **R4-b-R4** were taken up most likely *via* endocytosis, suggested by the punctuate fluorescence in the cells, while strong cytosolic uptake was observed at the higher concentrations, possibly *via* nucleation zones as has been reported before by us<sup>16</sup> and for arginine rich CPPs in general.<sup>31</sup> The concentration dependent uptake of arginine-rich CPPs has been described in the literature before, however, it was surprising that the concentration at which HeLa cells switched to a different uptake mechanism differed between the two similar peptides **R8** and **R4-b-R4**. From these results and for uniformity, we concluded that 5  $\mu\text{M}$  would be the best concentration to compare *in situ* activation for these small molecules.

### *In situ* activation

The efficient cellular uptake of the **R4-b-R4** peptide, prompted us to study the *in situ* activation of oligo-arginines using the bioorthogonal tetrazine ligation. We commenced by co-incubating HeLa cells with 5  $\mu\text{M}$  **R4-Tz** in serum-containing culture medium and added 5 eq. of **BCN-R4** to allow ligation and formation of **R4-b-R4**. We included **R8** as positive control, while **R4-Tz** served as negative control. As seen by CLSM, the uptake of *in situ* activated **R4-Tz** + **BCN-R4** at 30 minutes was similar to the uptake of **R8** as well as **R4-b-R4**, indicating that *in situ* activation of **R4-Tz** to **R4-b-R4** is possible at these conditions (Fig. 4 and S1†).

Next, we evaluated whether uptake could be improved by increasing the amount of activating agent **BCN-R4** or by prolonging the incubation time. We found that addition of 10 eq. of **BCN-R4** instead of 5 eq. did not improve uptake (Fig. S2†), while reducing the amount of **BCN-R4** from 5 eq. to 2.5 eq. resulted in a significant decrease in cellular uptake (Fig. S3†). Subsequently, we assessed the effect of incubation time on *in situ* activation of **R4-Tz**. Using similar conditions as above we observed CPP uptake already after 30 minutes and that uptake increased slightly over time. At 60 minutes, similar uptake levels were reached as observed after 90 minutes (Fig. S3†). From these results we concluded that 30–60 minutes of incubation using 5 eq. of **BCN-R4** activating agent are needed for sufficient CPP uptake.

To study the effect of the tetrazine ligation rate, we additionally prepared tetra-arginine fragments that were N-terminally equipped with either a norbornene (**Norb-R4**), or a *trans*-cyclooctene (**TCO-R4**) moiety (Fig. 2). Norbornene and TCO are known to display a respectively lower and higher reactivity towards tetrazines compared to BCN.<sup>25</sup> We compared the uptake of the *in situ* activation of **R4-Tz** by the tetra-arginines with the different bioorthogonal reagents using CLSM (Fig. 4A). To acquire the uptake efficiency more quantitatively, we additionally measured the cellular fluorescence of the various tetrazine reactions with flow cytometry (Fig. 4B). HeLa cells were incubated with **R8** at 5  $\mu\text{M}$  for 30 minutes at 37 °C in serum containing medium and compared to cells that were incubated for 30 minutes with 5  $\mu\text{M}$  **R4-Tz** to




Fig. 4 HeLa cell uptake studies to test *in situ* activation. (A) CLSM micrographs for HeLa cell uptake studies to test *in situ* activation. CLSM images are depicted for positive control **R8**, negative control **R4-Tz** and *in situ* activated **R4-Tz** + **BCN-R4**/**Norb-R4**/**TCO-R4**. For the *in situ* activation HeLa cells were incubated with 5  $\mu\text{M}$  **R4-Tz** and 5 eq. of **BCN-R4**/**Norb-R4**/**TCO-R4** for 30 minutes. (B) Flow cytometry results at 5  $\mu\text{M}$  in serum-containing medium for 30 minutes of incubation.

which 5 equivalents of **BCN-R4**, **Norb-R4**, or **TCO-R4** were added respectively. As shown in Fig. 4, truncated split **R4-Tz** again hardly gave any uptake. Interestingly, the **R4-Tz** peptide incubated with **Norb-R4** showed only poor uptake while both activation with **BCN-R4** and **TCO-R4** gave uptake that was comparable to reference peptide **R8**. Interestingly, no significant difference was found between BCN and TCO.

### Protein cargo

As our activation strategy is feasible using an iEDDA conjugation reaction for a small molecule fluorophore we next explored whether our strategy could also be used for the induced uptake of a much larger protein cargo. To this end we selected fluorescently labelled human serum albumin (HSA) as a model protein. This 66 kDa protein contains a single free cysteine that allowed us to site selectively modify the protein with a tetrazine. This was achieved by first reacting the cysteine of HSA with a bi-functional maleimide-DBCO linker and reaction of free lysines of HSA with








Fig. 5 HSA conjugates and HeLa cell uptake studies to test *in situ* activation. (A) Structures of the molecules used to modify HSA. (B) Confocal fluorescence images at 10  $\mu$ M in serum-containing medium for 90 minutes of incubation. (C) Flow cytometry results under the same conditions.

FITC providing fluorescent HSA-DBCO. A tetra-arginine with an N-terminal azide and a C-terminal tetrazine, **N3-R4-Tz**, was conjugated in a sequential step yielding **HSA-R4-Tz** (Fig. 5A). In addition, we prepared an octa-arginine protein conjugate (**HSA-R8**) using **N3-R8**, for comparison.

Using HSA as cargo conjugated to a tetrazine oligo-arginine, activation with the **BCN-R4** peptide under the conditions employed above, we did not observe significant cellular uptake as evidenced by FACS as well as confocal microscopy. Fortunately, incubation at a slightly higher concentration (10  $\mu$ M) and increased time (90 min) resulted in clear uptake of the **HSA-R4-Tz** protein which was *in situ* activated by conjugation to **BCN-R4** (Fig. 5B). Similar uptake levels were observed for **HSA-R8** while unreacted **HSA-R4-Tz** was only poorly taken up. These qualitative results were quantified using flow cytometry using the same conditions (Fig. 5C) and substantiate that our *in situ* CPP activation strategy is suitable for the delivery of a large protein cargo.

## Conclusions

In conclusion, we have successfully developed an *in situ* activation strategy for oligo-arginine CPPs based on a bio-orthogonal tetrazine ligation between two split tetra-arginine parts. The norbornene-based reaction did not show kinetics suitable for *in situ* application, but both BCN and TCO were efficient in reconstituting active CPPs. This provides a valuable method for probe design and is the basis for further efforts in this line of research. Moreover, using BCN efficient cellular

uptake was observed for a low molecular weight fluorescent probe as well as a large protein cargo. Future efforts in this line of research are to incorporate homing peptides or targeting ligands<sup>33</sup> in our tetra-arginine activation strategy, providing the first steps towards a targeted and site-selective cargo delivery strategy involving activatable CPPs.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The department of General Instruments of the Radboud University, and Elisabeth Pierson in particular, is acknowledged for providing microscopy services.

## Notes and references

- D. Zhang, J. Wang and D. Xu, *J. Controlled Release*, 2016, **229**, 130–139.
- F. Wang, Y. Wang, X. Zhang, W. Zhang, S. Guo and F. Jin, *J. Controlled Release*, 2014, **174**, 126–136.
- K. Kurrikoff, M. Gestin and Ü. Langel, *Expert Opin. Drug Delivery*, 2016, **13**, 373–387.
- A. Komin, L. M. Russell, K. A. Hristova and P. C. Searson, *Adv. Drug Delivery Rev.*, 2017, **110–111**, 52–64.
- L. Fení and I. Neundorff, The Current Role of Cell-Penetrating Peptides in Cancer Therapy, in *Peptides and Peptide-based Biomaterials and their Biomedical Applications*, Advances in Experimental Medicine and Biology, ed. A. Sunna, A. Care and P. Bergquist, Springer, Cham, 2017, vol. 1030, pp. 279–295.
- Y. Huang, Y. Jiang, H. Wang, J. Wang, M. C. Shin, Y. Byun, H. He, Y. Liang and V. C. Yang, *Adv. Drug Delivery Rev.*, 2013, **65**, 1299–1315.
- Q. Zhang, H. Gao and Q. He, *Mol. Pharm.*, 2015, **12**, 3105–3118.
- E. Vives, *J. Controlled Release*, 2005, **109**, 77–85.
- S. R. MacEwan and A. Chilkoti, *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.*, 2013, **5**, 31–48.
- E. Jin, B. Zhang, X. Sun, Z. Zhou, X. Ma, Q. Sun, J. Tang, Y. Shen, E. Van Kirk, W. J. Murdoch and M. Radosz, *J. Am. Chem. Soc.*, 2013, **135**, 933–940.
- M. B. Hansen, E. van Gaal, I. Minten, G. Storm, J. C. M. van Hest and D. W. P. M. Löwik, *J. Controlled Release*, 2012, **164**, 87–94.
- J. Wang, S. Shen, D. Li, C. Zhan, Y. Yuan and X. Yang, *Adv. Funct. Mater.*, 2018, **28**, 1704806.
- A. Prestel and H. M. Moller, *Chem. Commun.*, 2016, **52**, 701–704.
- T. Jiang, E. S. Olson, Q. T. Nguyen, M. Roy, P. A. Jennings and R. Y. Tsien, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 17867–17872.
- S. A. Bode, M. B. Hansen, R. A. J. F. Oerlemans, J. C. M. van Hest and D. W. P. M. Löwik, *Bioconjugate Chem.*, 2015, **26**, 850–856.



- 16 S. A. Bode, R. Wallbrecher, R. Brock, J. C. M. van Hest and D. W. P. M. Löwik, *Chem. Commun.*, 2014, **50**, 415–417.
- 17 S. A. Bode, I. C. Kruis, H. P. J. H. M. Adams, W. C. Boelens, G. J. M. Pruijn, J. C. M. van Hest and D. W. P. M. Löwik, *ChemBioChem*, 2017, **18**, 185–188.
- 18 S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda and Y. Sugiura, *J. Biol. Chem.*, 2001, **276**, 5836–5840.
- 19 E. G. Stanzl, B. M. Trantow, J. R. Vargas and P. A. Wender, *Acc. Chem. Res.*, 2013, **46**, 2944–2954.
- 20 D. M. Patterson and J. A. Prescher, *Curr. Opin. Chem. Biol.*, 2015, **28**, 141–149.
- 21 J. Sauer, D. K. Heldmann, J. Hetzenegger, J. Krauthan, H. Sichert and J. Schuster, *Eur. J. Org. Chem.*, 1998, 2885–2896.
- 22 R. Selvaraj and J. M. Fox, *Curr. Opin. Chem. Biol.*, 2013, **17**, 753–760.
- 23 J. Seckute and N. K. Devaraj, *Curr. Opin. Chem. Biol.*, 2013, **17**, 761–767.
- 24 K. Lang and S. Mayer, *Synthesis*, 2016, **49**, 830–848.
- 25 B. L. Oliveira, Z. Guo and G. J. L. Bernardes, *Chem. Soc. Rev.*, 2017, **46**, 4895–4950.
- 26 R. Rossin, R. M. Versteegen, J. Wu, A. Khasanov, H. J. Wessels, E. J. Steenbergen, W. Ten Hoeve, H. M. Janssen, A. van Onzen, P. J. Hudson and M. S. Robillard, *Nat. Commun.*, 2018, **9**, 1484.
- 27 M. R. Karver, R. Weissleder and S. A. Hilderbrand, *Bioconjugate Chem.*, 2011, **22**, 2263–2270.
- 28 A. C. Knall and C. Slugovc, *Chem. Soc. Rev.*, 2013, **42**, 5131–5142.
- 29 J. Dommerholt, S. Schmidt, R. Temming, L. J. A. Hendriks, F. P. J. T. Rutjes, J. C. M. van Hest, D. J. Lefeber, P. Friedl and F. L. van Delft, *Angew. Chem., Int. Ed.*, 2010, **49**, 9422–9425.
- 30 R. Brock, *Bioconjugate Chem.*, 2014, **25**, 863–868.
- 31 T. Takeuchi and S. Futaki, *Chem. Pharm. Bull.*, 2016, **64**, 1431–1437.
- 32 A. Kuzmin, A. Poloukhine, M. A. Wolfert and V. V. Popik, *Bioconjugate Chem.*, 2010, **21**, 2076–2085.
- 33 M. Wang, D. Svatunek, K. Rohlfing, Y. Liu, H. Wang, B. Giglio, H. Yuan, Z. Wu, Z. Li and J. Fox, *Theranostics*, 2016, **6**, 887–895.

